Form 4 Filing for Artiva Biotherapeutics, Inc. - Officer/Director Transaction

This Form 4 filing reports a transaction by Fred Aslan, Chief Executive Officer and Director of Artiva Biotherapeutics, Inc. On May 19, 2026, Aslan disposed of 27,116 shares of Common Stock with a weighted average sale price of $9.0077. The sale was executed under a "sell-to-cover" policy to satisfy tax withholding obligations related to the vesting of restricted stock units. These sales were automatic and not at Aslan's discretion. Following this transaction, Aslan directly owns 1,535,082 shares of common stock. The sale price ranged from $8.7383 to $9.0104.